PDPL — Parenteral Drugs (India) Income Statement
0.000.00%
Last trade - 00:00HealthcareBalancedMicro Cap
Annual income statement for Parenteral Drugs (India), fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2018 March 31st | 2019 March 31st | 2020 March 31st | 2021 March 31st | 2022 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | IAS | IAS | IAS | IAS | — |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 2,171 | 320 | 319 | 122 | 85 |
| Cost of Revenue | |||||
| Gross Profit | 607 | 256 | 256 | 65 | 30.3 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 2,624 | 1,188 | 639 | 413 | 637 |
| Operating Profit | -453 | -868 | -320 | -291 | -552 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -1,412 | -1,814 | -1,417 | -1,545 | -1,091 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -1,189 | -1,479 | -1,141 | -1,217 | -764 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -1,189 | -1,479 | -1,141 | -1,217 | -764 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -1,189 | -1,479 | -1,141 | -1,217 | -764 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -39.9 | -49.6 | -38.3 | -40.9 | -37 |